Marina Says Cash Will Run out at the End of the Month, Reports 2011 Financials | GenomeWeb

Roughly six months after stating that it could not file its 2011 annual report on time due to “financial and strategic uncertainties,” Marina Biotech has released its financial results for last year and, in doing so, disclosed that it will be out of money by the end of October.

As of Dec. 31, 2011, Marina had just $2 million in cash, $1 million of which was restricted, it said in filing with the US Securities and Exchange Commission released last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.